Lantheus licensed exclusive worldwide rights (excluding certain territories) to PNT2003 from POINT Biopharma Global, Inc. in December 2022. To read the press release announcing that licensing ...
Tentative approval for PNT2003 positions it as the first FDA-cleared radioequivalent of Lu 177 dotatate, with anticipated ...
Review the side-effects of Lutetium Lu 177 Dotatate as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...
Discover comprehensive details about Lutetium Lu 177 Dotatate, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...
ST. LOUIS, July 09, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has submitted its 505(b)(2) New Drug Application for Lutetium Lu 177 Dotatate Injection ...
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...
The newly developed [55Co]55Co-DOTATATE imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases. According to research ...
A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results